 Protagonist Therapeutics Inc NASDAQ: PTGX announced topline results from the Phase 2 IDEAL study of PN-943 in moderate-to-severe ulcerative colitis UC patients. 159 patients with moderate-to-severe active UC were randomized to either twice daily BID with 450 mg or 150 mg PN-. 